Global Spending on Neglected Disease Research and Development
Author Information
Author(s): Mary Moran, Javier Guzman, Anne-Laure Ropars, Alina McDonald, Nicole Jameson, Brenda Omune, Sam Ryan, Lindsey Wu
Primary Institution: George Institute for International Health
Hypothesis
How much are we really spending on research and development for neglected diseases?
Conclusion
The survey found that just over $2.5 billion was invested into R&D of new neglected disease products in 2007, with funding heavily concentrated on HIV/AIDS, TB, and malaria.
Supporting Evidence
- Funding for HIV/AIDS, TB, and malaria accounted for nearly 80% of total R&D investment.
- Public and philanthropic donors provided 90% of the total funding in 2007.
- Only 12 organizations provided around 80% of global funding for neglected diseases.
Takeaway
This study looked at how much money is being spent to create new medicines for diseases that mostly affect poor countries, and found that a lot of it goes to just a few diseases.
Methodology
The G-FINDER survey collected raw primary data from funders and product developers about their investments in neglected disease R&D.
Potential Biases
Potential bias due to varying levels of responsiveness from different organizations and countries.
Limitations
The survey may underreport private sector funding due to non-participation of major pharmaceutical companies and incomplete data from others.
Participant Demographics
The survey included public, private, and philanthropic funders from high- and middle-income countries.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website